Inmed pharmaceuticals provides update on its core research and development programs and baymedica business

Vancouver, british columbia, sept. 08, 2022 (globe newswire) -- inmed pharmaceuticals inc. (“inmed” or the “company”) (nasdaq: inm), a leader in the research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announces an update on its research/development and commercial activities.
INM Ratings Summary
INM Quant Ranking